Reed ingress medicine ® has been approved in Hong Kong for the treatment of epithelial ovarian cancer patients

recently, thePharmaceutical(NASDAQ: ZLAB) announced that the ® (ZEJULA ®, Niraparib) has been approved in Hong Kong for the treatment of patients with platinum-sensitive recurrent high-level slurry hypertherclustic ovarian cancer with platinum-containing chemotherapy (CR) or partial remission (PR)® is a poly (ADP-ribose) polymerase (PARP) inhibitor, orally once a dayUnlike other PARP inhibitors approved in Hong Kong, Le ® do not need to perform BRCA or other biomarkertest
() prior to administrationrelated research
the approval of this ® in Hong Kong is based on the findings of the International Phase III ClinicalTrial(ENGOT-OV16/NOVA)the study, initiated by TESARO, a partner in Reding Pharmaceuticals, was a double-blind, placebo-controlled study of 553 platinum-sensitive patients with high levels of platinum recurrent plasma cancer, fallopian tube cancer, or primary peritoneal cancer, defined as the penultimate platinum-containing chemotherapy after full or partial remission of more than 6 monthsThe main endpoint of thestudy was progressionless survival (PFS), and about two-thirds of the enrolled patients did not have a BRCA mutationIn NOVA studies, disease progression is determined by a robust, unbiased, and blind central assessment that predates radiological testing or clinical progressionCompared to the control group, the ® significantly extended PFS, regardless of whether the patient had a BRCA mutation in the embryotreatment with the ® reduced the risk of disease progression or death by 73% (risk ratio (HR) 0.27) in patients with BRCA mutations, and 55% (HR 0.45) in patients without the BRCA mutation Patients with platinum-containing chemotherapy that achieve solely or partial remission can benefit from the maintenance treatment of the ®